Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL [0.03%]
Lisocabtagene Maraleucel治疗复发/难治性FL患者疗效持久且安全性良好：TRANSCEND FL试验3年随访结果
Sairah Ahmed,Alejandro Martin Garcia-Sancho,Juan Luis Reguera-Ortega et al.
Sairah Ahmed et al.
In the TRANSCEND FL primary analysis, lisocabtagene maraleucel (liso-cel) showed high response rates and favorable safety in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Longer follow-up is needed to assess remission du...
R spondin 2 regulates regeneration of the hematopoietic stem cell niche [0.03%]
R spondin 2调节造血干细胞生态位的再生
Vanessa N Montinelli,Samantha Grohe,Xue Ying Song et al.
Vanessa N Montinelli et al.
Hematopoietic stem cells (HSCs) depend upon paracrine signals from bone marrow endothelial cells (BM ECs) and perivascular stromal cells for their maintenance and regeneration. Chemotherapy and total body irradiation (TBI) utilized in the c...
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations [0.03%]
伊布替尼联合维奈克拉治疗≥65岁或TP53突变型非blastoid型套细胞淋巴瘤患者的一线方案疗效评估研究
Michael Wang,Marc S Hoffmann,Tomasz Wróbel et al.
Michael Wang et al.
The phase 3 SYMPATICO study included an open-label cohort to evaluate the efficacy and safety of first-line ibrutinib plus venetoclax in patients with non-blastoid mantle cell lymphoma (MCL) ≥65 years (n=65), or ≥18 years with a TP53 muta...
Hansen J Kosasih,Charles E de Bock
Hansen J Kosasih
Hrishikesh K Srinagesh,Lori S Muffly
Hrishikesh K Srinagesh
Yvette Y Yien
Yvette Y Yien
Manali Kamdar
Manali Kamdar
Marie A Hollenhorst
Marie A Hollenhorst
Xun Grace Wu,Heyu Ni
Xun Grace Wu